Thomas K. Equels, the CEO and President of AIM ImmunoTech Inc., recently acquired 20,299 shares of the company's common stock. This transaction, reported on November 6, 2026, highlights Equels' commitment to the company and its future prospects.

AIM ImmunoTech Inc. operates in the biological products sector, focusing on innovative health solutions. The company is incorporated in Delaware and has its headquarters in Ocala, Florida. AIM ImmunoTech trades under the ticker symbol AIM.

The filing indicates that Equels purchased the shares at a price of $0.156 each. Following this acquisition, he now owns a total of 210,046 shares in the company. The filing states, "Transaction Code: P" indicating a purchase of shares.

This acquisition may have implications for AIM ImmunoTech's stakeholders, as it reflects Equels' confidence in the company's direction and performance. Increased executive ownership can often lead to positive perceptions among investors and analysts, suggesting that leadership is aligned with shareholder interests.

The filing does not specify what actions may follow this acquisition or if there will be further disclosures regarding Equels' ownership strategy.

Details of the Acquisition

The acquisition of 20,299 shares by Thomas K. Equels was executed on November 6, 2026, under transaction code 'P,' which designates a purchase. This transaction was made at a price of $0.156 per share, indicating a total investment of approximately $3,168.84. Following this transaction, Equels now holds a total of 210,046 shares of AIM ImmunoTech Inc.

Executive Role and Ownership

Equels serves as both the CEO and President of AIM ImmunoTech Inc., a role that positions him as a key decision-maker within the company. The filing indicates that he is also a director, further solidifying his influence over the company's strategic direction. His direct ownership of shares, as noted in the filing, reflects his vested interest in the company's performance and future growth.

Company Background

AIM ImmunoTech Inc. is classified under the Standard Industrial Classification (SIC) code 2836, which pertains to biological products that do not include diagnostic substances. The company is incorporated in Delaware and has its operational headquarters located at 2117 SW Highway 484, Ocala, Florida. AIM ImmunoTech is publicly traded under the ticker symbol AIM and has a fiscal year that ends on December 31.

"The filing does not provide information on the potential impact of this acquisition on AIM ImmunoTech's stock performance or any future plans for additional share purchases by Equels."